Population-based risk assessment of APOL1 on renal disease

David J. Friedman, Julia Kozlitina, Giulio Genovese, Prachi Jog, Martin R. Pollak

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Case-control studies suggest that African Americans with genetic variants in both copies of APOL1 have increased risk for hypertension-attributable ESRD and focal segmental glomerulosclerosis. Here, we tested these risk variants in the Dallas Heart Study to ascertain the prevalence of APOL1-associated renal disease in a large population-based study and to estimate the contribution of APOL1 risk variants to disparities in renal disease. We determined the genotype of 1825 African Americans and 1042 European Americans. Among participants without diabetes, we identified microalbuminuria in 2.3% of European Americans, 6.0% of African Americans with no or one APOL1 risk allele, and 16.5% of African Americans with two risk alleles. In addition, the proportions of participants with estimated GFR < 60 ml/min per 1.73 m 2 was 1.5% for nondiabetic European Americans, 1.7% for African Americans with no or one APOL1 risk allele, and 6.7% for African Americans with two risk alleles. The APOL1 genotype did not associate with any differences in rates of CKD for study participants with diabetes. Our data suggest that more than 3 million African Americans likely have the high-risk genotype and are at markedly increased risk for nondiabetic CKD. In contrast, African Americans without the risk genotype and European Americans appear to have similar risk for developing nondiabetic CKD.

Original languageEnglish (US)
Pages (from-to)2098-2105
Number of pages8
JournalJournal of the American Society of Nephrology
Volume22
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

African Americans
Kidney
Population
Alleles
Genotype
Focal Segmental Glomerulosclerosis
Chronic Kidney Failure
Case-Control Studies
Hypertension

ASJC Scopus subject areas

  • Nephrology

Cite this

Population-based risk assessment of APOL1 on renal disease. / Friedman, David J.; Kozlitina, Julia; Genovese, Giulio; Jog, Prachi; Pollak, Martin R.

In: Journal of the American Society of Nephrology, Vol. 22, No. 11, 11.2011, p. 2098-2105.

Research output: Contribution to journalArticle

Friedman, David J. ; Kozlitina, Julia ; Genovese, Giulio ; Jog, Prachi ; Pollak, Martin R. / Population-based risk assessment of APOL1 on renal disease. In: Journal of the American Society of Nephrology. 2011 ; Vol. 22, No. 11. pp. 2098-2105.
@article{7005f87b7ee642be912ad32ee52a4533,
title = "Population-based risk assessment of APOL1 on renal disease",
abstract = "Case-control studies suggest that African Americans with genetic variants in both copies of APOL1 have increased risk for hypertension-attributable ESRD and focal segmental glomerulosclerosis. Here, we tested these risk variants in the Dallas Heart Study to ascertain the prevalence of APOL1-associated renal disease in a large population-based study and to estimate the contribution of APOL1 risk variants to disparities in renal disease. We determined the genotype of 1825 African Americans and 1042 European Americans. Among participants without diabetes, we identified microalbuminuria in 2.3{\%} of European Americans, 6.0{\%} of African Americans with no or one APOL1 risk allele, and 16.5{\%} of African Americans with two risk alleles. In addition, the proportions of participants with estimated GFR < 60 ml/min per 1.73 m 2 was 1.5{\%} for nondiabetic European Americans, 1.7{\%} for African Americans with no or one APOL1 risk allele, and 6.7{\%} for African Americans with two risk alleles. The APOL1 genotype did not associate with any differences in rates of CKD for study participants with diabetes. Our data suggest that more than 3 million African Americans likely have the high-risk genotype and are at markedly increased risk for nondiabetic CKD. In contrast, African Americans without the risk genotype and European Americans appear to have similar risk for developing nondiabetic CKD.",
author = "Friedman, {David J.} and Julia Kozlitina and Giulio Genovese and Prachi Jog and Pollak, {Martin R.}",
year = "2011",
month = "11",
doi = "10.1681/ASN.2011050519",
language = "English (US)",
volume = "22",
pages = "2098--2105",
journal = "Journal of the American Society of Nephrology",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "11",

}

TY - JOUR

T1 - Population-based risk assessment of APOL1 on renal disease

AU - Friedman, David J.

AU - Kozlitina, Julia

AU - Genovese, Giulio

AU - Jog, Prachi

AU - Pollak, Martin R.

PY - 2011/11

Y1 - 2011/11

N2 - Case-control studies suggest that African Americans with genetic variants in both copies of APOL1 have increased risk for hypertension-attributable ESRD and focal segmental glomerulosclerosis. Here, we tested these risk variants in the Dallas Heart Study to ascertain the prevalence of APOL1-associated renal disease in a large population-based study and to estimate the contribution of APOL1 risk variants to disparities in renal disease. We determined the genotype of 1825 African Americans and 1042 European Americans. Among participants without diabetes, we identified microalbuminuria in 2.3% of European Americans, 6.0% of African Americans with no or one APOL1 risk allele, and 16.5% of African Americans with two risk alleles. In addition, the proportions of participants with estimated GFR < 60 ml/min per 1.73 m 2 was 1.5% for nondiabetic European Americans, 1.7% for African Americans with no or one APOL1 risk allele, and 6.7% for African Americans with two risk alleles. The APOL1 genotype did not associate with any differences in rates of CKD for study participants with diabetes. Our data suggest that more than 3 million African Americans likely have the high-risk genotype and are at markedly increased risk for nondiabetic CKD. In contrast, African Americans without the risk genotype and European Americans appear to have similar risk for developing nondiabetic CKD.

AB - Case-control studies suggest that African Americans with genetic variants in both copies of APOL1 have increased risk for hypertension-attributable ESRD and focal segmental glomerulosclerosis. Here, we tested these risk variants in the Dallas Heart Study to ascertain the prevalence of APOL1-associated renal disease in a large population-based study and to estimate the contribution of APOL1 risk variants to disparities in renal disease. We determined the genotype of 1825 African Americans and 1042 European Americans. Among participants without diabetes, we identified microalbuminuria in 2.3% of European Americans, 6.0% of African Americans with no or one APOL1 risk allele, and 16.5% of African Americans with two risk alleles. In addition, the proportions of participants with estimated GFR < 60 ml/min per 1.73 m 2 was 1.5% for nondiabetic European Americans, 1.7% for African Americans with no or one APOL1 risk allele, and 6.7% for African Americans with two risk alleles. The APOL1 genotype did not associate with any differences in rates of CKD for study participants with diabetes. Our data suggest that more than 3 million African Americans likely have the high-risk genotype and are at markedly increased risk for nondiabetic CKD. In contrast, African Americans without the risk genotype and European Americans appear to have similar risk for developing nondiabetic CKD.

UR - http://www.scopus.com/inward/record.url?scp=80555148891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80555148891&partnerID=8YFLogxK

U2 - 10.1681/ASN.2011050519

DO - 10.1681/ASN.2011050519

M3 - Article

VL - 22

SP - 2098

EP - 2105

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 11

ER -